» Articles » PMID: 28423234

Pulmonary Vein Isolation with Concomitant Renal Artery Denervation is Associated with Reduction in Both Arterial Blood Pressure and Atrial Fibrillation Burden: Data from Implantable Cardiac Monitor

Overview
Journal Cardiovasc Ther
Publisher Hindawi
Date 2017 Apr 20
PMID 28423234
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Renal artery denervation (RDN) has provided incremental atrial fibrillation (AF) suppression after pulmonary vein isolation (PVI) in patients with AF in the setting of drug-resistant hypertension.

Objective: To assess the relationship between changes of mean blood pressure (BP) and AF recurrences/AF burden after PVI combined with RDN.

Methods: All patients from two randomized studies with symptomatic paroxysmal AF and/or persistent AF and resistant hypertension who underwent PVI-only (n=37) or PVI with RDN (n=39), and implantable cardiac monitor (ICM) implantation were eligible for this study. Mixed-effects linear models were used to investigate the effect of RDN on mean BP and mean AF burden and associations between the two during the 12-month follow-up.

Results: Concomitant RDN was associated with a significant reduction in both mean AF burden (2.43 [95% CI: 1.76-3.09] % vs 6.95 [95% CI: 5.44-8.45] %) and mean BP (104 [95% CI: 103-106] mm Hg vs 112 [95% CI: 110-113] mm Hg). Decrease in mean BP was positively correlated with decline in mean AF burden: reduction of 5-10 mm Hg was accompanied by a 7.0% decreased mean AF burden, with greater reduction (up to 20 mm Hg) associated with on average 17.7% lower mean AF burden.

Conclusions: Renal artery denervation when added to PVI decreases AF recurrences, AF burden, and mean BP. Reduction in mean BP is associated with both AF burden and recurrences. Further large-scale studies are needed to define the mechanistic pathway(s) of the antiarrhythmic effects of RDN.

Citing Articles

Hypertension and Atrial Fibrillation: Bridging the Gap Between Mechanisms, Risk, and Therapy.

Antoun I, Layton G, Nizam A, Barker J, Abdelrazik A, Eldesouky M Medicina (Kaunas). 2025; 61(2).

PMID: 40005478 PMC: 11857777. DOI: 10.3390/medicina61020362.


Efficacy of renal denervation as an adjunct to pulmonary vein isolation for atrial fibrillation treatment: a systematic review and meta-analysis.

Thavabalan K, Sheikh M, Phuah Y, Rajput S, Fatima N, Sutaria A Eur Heart J Open. 2024; 4(4):oeae065.

PMID: 39175848 PMC: 11340072. DOI: 10.1093/ehjopen/oeae065.


Emerging Role of Renal Sympathetic Denervation as an Adjunct Therapy to Atrial Fibrillation Ablation.

Akrawinthawong K, Yamada T Rev Cardiovasc Med. 2024; 25(4):122.

PMID: 39076548 PMC: 11264041. DOI: 10.31083/j.rcm2504122.


Atrial fibrillation: primary prevention, secondary prevention, and prevention of thromboembolic complications: part 1.

Trohman R, Huang H, Sharma P Front Cardiovasc Med. 2023; 10:1060030.

PMID: 37396596 PMC: 10311453. DOI: 10.3389/fcvm.2023.1060030.


Renal denervation for atrial fibrillation: a comprehensive updated systematic review and meta-analysis.

Nawar K, Mohammad A, Johns E, Abdulla M J Hum Hypertens. 2022; 36(10):887-897.

PMID: 35094013 PMC: 9553644. DOI: 10.1038/s41371-022-00658-0.